Longeveron says ELPIS II trial of laromestrocel in hypoplastic left heart syndrome misses primary endpoint

PUBT · 1d ago
Longeveron says ELPIS II trial of laromestrocel in hypoplastic left heart syndrome misses primary endpoint
  • Longeveron reported topline results from its ELPIS II Phase 2b trial of laromestrocel in infants with hypoplastic left heart syndrome.
  • The study missed its main efficacy goal, raising uncertainty over the program’s near-term regulatory path.
  • Exploratory findings suggested potential benefits in longer-term outcomes, though the signals were not statistically conclusive.
  • Safety and tolerability remained consistent with prior studies, with no new safety issues flagged in the trial.
  • A strategic review was launched to maximize shareholder value, including plans to hire an investment bank and tighten spending.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Longeveron Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609161727PRIMZONEFULLFEED9828546) on September 16, 2026, and is solely responsible for the information contained therein.